BioCentury | Jan 22, 2002
Clinical News

Extended release tramadol: CLC's Cipher Pharmaceuticals Inc. subsidiary submitted an IND to begin U.S. and Canadian Phase II testing of its once-daily tramadol

Canadian Medical Laboratories Ltd. (TSE:CLC), Mississauga, Ontario Product: Extended release tramadol Business: Neurological Therapeutic category: Analgesic, Neurotransmission Target: Opioid receptors, noradrenaline and serotonin Description: Once-daily formulation of Johnson & Johnson 's Ultram Indication: Treat pain...
BioCentury | Oct 22, 2001
Clinical News

Budesonide Dry Powder Inhaler: Began Phase III study

Canadian Medical Laboratories Ltd. (TSE:CLC), Mississauga, Ontario Product: Budesonide Dry Powder Inhaler Business: Autoimmune/Inflammation Therapeutic category: Steroid Target: Immune cells Description: Inhaled dry powder formulation of corticosteroid Indication: Treat or prevent asthma Endpoint: Safety, pharmacokinetics...
BioCentury | Sep 25, 2001
Company News

Cipher, AstraZeneca in asthma deal

...Cipher Pharmaceuticals, a subsidiary of Canadian Medical Laboratories (TSE:CLC), received exclusive rights in the Americas from Galephar (San...
BioCentury | Jan 29, 2001
Company News

Canadian Medical Laboratories, Galephar P.R. Inc. deal

...exclusive rights to the product in the Americas and non-exclusive rights elsewhere outside of Europe. Canadian Medical Laboratories Ltd....
Items per page:
1 - 4 of 4
BioCentury | Jan 22, 2002
Clinical News

Extended release tramadol: CLC's Cipher Pharmaceuticals Inc. subsidiary submitted an IND to begin U.S. and Canadian Phase II testing of its once-daily tramadol

Canadian Medical Laboratories Ltd. (TSE:CLC), Mississauga, Ontario Product: Extended release tramadol Business: Neurological Therapeutic category: Analgesic, Neurotransmission Target: Opioid receptors, noradrenaline and serotonin Description: Once-daily formulation of Johnson & Johnson 's Ultram Indication: Treat pain...
BioCentury | Oct 22, 2001
Clinical News

Budesonide Dry Powder Inhaler: Began Phase III study

Canadian Medical Laboratories Ltd. (TSE:CLC), Mississauga, Ontario Product: Budesonide Dry Powder Inhaler Business: Autoimmune/Inflammation Therapeutic category: Steroid Target: Immune cells Description: Inhaled dry powder formulation of corticosteroid Indication: Treat or prevent asthma Endpoint: Safety, pharmacokinetics...
BioCentury | Sep 25, 2001
Company News

Cipher, AstraZeneca in asthma deal

...Cipher Pharmaceuticals, a subsidiary of Canadian Medical Laboratories (TSE:CLC), received exclusive rights in the Americas from Galephar (San...
BioCentury | Jan 29, 2001
Company News

Canadian Medical Laboratories, Galephar P.R. Inc. deal

...exclusive rights to the product in the Americas and non-exclusive rights elsewhere outside of Europe. Canadian Medical Laboratories Ltd....
Items per page:
1 - 4 of 4